keyword
MENU ▼
Read by QxMD icon Read
search

neo-adjuvant chemotherapy

keyword
https://www.readbyqxmd.com/read/28611280/efficacy-of-adjuvant-chemotherapy-with-carboplatin-for-early-triple-negative-breast-cancer-a-single-center-experience
#1
Marcus Vetter, Spyridon Fokas, Ewelina Biskup, Thomas Schmid, Fabienne Schwab, Andreas Schoetzau, Uwe Güth, Christoph Rochlitz, Rosanna Zanetti-Dällenbach
BACKGROUND: Anthracycline- and taxane-based adjuvant chemotherapies are the most frequently used systemic treatments for women with triple negative breast cancer (TNBC). Adding platinum derivatives in the neo-adjuvant setting has been shown to not only improve the pCR rates, but also the 3 year DFS for TNBC patients; however, data on platinum derivatives in the adjuvant setting are limited. METHODS: We conducted a retrospective, single-center study in a Swiss breast cancer cohort to evaluate the role of carboplatin in addition to standard adjuvant therapy (anthracyclines and/ or taxanes) in early TNBC patients...
May 23, 2017: Oncotarget
https://www.readbyqxmd.com/read/28596034/breast-implant-associated-anaplastic-large-cell-lymphoma-the-uk-experience-recommendations-on-its-management-and-implications-for-informed-consent
#2
L Johnson, J M O'Donoghue, N McLean, P Turton, A A Khan, S D Turner, A Lennard, N Collis, M Butterworth, G Gui, J Bristol, J Hurren, S Smith, K Grover, G Spyrou, K Krupa, I A Azmy, I E Young, J J Staiano, H Khalil, F A MacNeill
BACKGROUND: Breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL) is a rare, Non-Hodgkin lymphoma arising in the capsule of breast implants. BIA-ALCL presents as a recurrent effusion and/or mass. Tumours exhibit CD30 expression and are negative for Anaplastic Lymphoma Kinase (ALK). We report the multi-disciplinary management of the UK series and how the stage of disease may be used to stratify treatment. METHODS: Between 2012 and 2016, 23 cases of BIA-ALCL were diagnosed in 15 regional centres throughout the UK...
May 18, 2017: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28583790/transanal-endoscopic-microsurgery-after-neoadjuvant-radiochemotherapy-for-locally-advanced-extraperitoneal-rectal-cancer
#3
G Rizzo, G Zaccone, M Magnocavallo, C Mattana, D P Pafundi, M A Gambacorta, V Valentini, C Coco
PURPOSE: The aim of this study is to provide a prospective analysis of post-operative and oncological outcomes in patients affected by locally advanced rectal cancer (LARC), who obtained a major/complete clinical response after pre-operative radio-chemotherapy (RCT) and were treated with local excision (LE) by trans-anal endoscopic microsurgery (TEM) to confirm a pathological complete response (pCR) after to neo-adjuvant RCT. METHODS: All patients with LARC treated by pre-operative RCT and full-thickness LE by TEM (2000-2014) were included in the study...
May 25, 2017: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28582270/conversion-for-unfavorable-intraoperative-events-results-in-significantly-worst-outcomes-during-laparoscopic-liver-resection-lessons-learned-from-a-multicenter-review-of-2861-cases
#4
Mark C Halls, Federica Cipriani, Giammauro Berardi, Leonid Barkhatov, Panagiotis Lainas, Mohammed Alzoubi, Mathieu D'Hondt, Fernando Rotellar, Ibrahim Dagher, Luca Aldrighetti, Roberto I Troisi, Bjorn Edwin, Mohammed Abu Hilal
OBJECTIVE: To investigate the risk factors for conversion during laparoscopic liver resection and its effect on patient outcome in a large cohort of patients. Additional analysis of outcomes in patients who required conversion for unfavorable intraoperative findings and conversion for unfavorable intraoperative events will be performed to establish if the cause of conversion effects outcome. SUMMARY BACKGROUND DATA: Multiple previous studies demonstrate that laparoscopic liver surgery reduces intraoperative blood loss, hospital stay, and morbidity while maintaining comparable oncological and survival outcomes when compared with open liver resections...
June 2, 2017: Annals of Surgery
https://www.readbyqxmd.com/read/28571778/long-term-outcomes-in-ypt0-rectal-cancers-an-international-multi-centric-investigation-on-behalf-of-italian-society-of-surgical-oncology-young-board-ysico
#5
L Lorenzon, D Parini, D Rega, A Mellano, V Vigorita, A Biondi, R Jaminez-Rosellon, M Scheiterle, I Giannini, G Gallo, G Marino, L Turati, P Marsanic, L De Franco, L Marano, R De Luca
AIM: To investigate the outcome and pattern of survivals of rectal cancer patients presenting a complete or nearly complete tumor response after neo-adjuvant treatment. METHODS: Young surgeons <40 years old affiliated to the Italian Society of Surgical Oncology (YSICO) from 13 referral centers for colorectal cancer treatment, were invited to participate a retrospective study. Records from patients treated from 2005 to 2015 with a pathological diagnosis of ypT0/ypTis were retrieved and pooled in a common data-base for statistical purposes...
May 19, 2017: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28570008/a-comparison-of-p53-and-wt1-immunohistochemical-expression-patterns-in-tubo-ovarian-high-grade-serous-carcinoma-before-and-after-neoadjuvant-chemotherapy
#6
Laura Casey, Martin Köbel, Raji Ganesan, Simone Tam, Rajeev Prasad, Steffen Böhm, Michelle Lockley, Arjun J Jeyarajah, Eleanor Brockbank, Asma Faruqi, C Blake Gilks, Naveena Singh
AIMS: Treatment of patients with tubo-ovarian high-grade serous carcinoma (HGSC) is increasingly based on diagnosis on small biopsy samples and the first surgical specimen is often post-chemotherapy. p53 and WT1 are important diagnostic markers for HGSC. The effect of neo-adjuvant chemotherapy on p53 and WT1 expression has not been widely studied. We aimed to compare p53 and WT1 expression in paired pre- and post-chemotherapy samples of HGSC. METHODS AND RESULTS: Immunohistochemistry (IHC) was carried out for p53 and WT1 on paired omental HGSC samples pre- and post-chemotherapy...
June 1, 2017: Histopathology
https://www.readbyqxmd.com/read/28559118/tumor-regression-grades-k-ras-mutational-profile-and-c-met-in-colorectal-liver-metastases
#7
Laura Lorenzon, Luana Ricca, Emanuela Pilozzi, Antoinette Lemoine, Valentina Riggio, Maria Teresa Giudice, Giuseppe Mallel, Flavio Fochetti, Genoveffa Balducci
INTRODUCTION: Recently TRG, necrosis grade and the rate of viable cancer cells of colorectal liver metastases were correlated with the response to chemotherapy treatments, whereas K-RAS mutations and c-MET over-expression were correlated with the prognosis. METHODS: 58 resection specimens were assessed for regression grades. Patients undergone neo-adjuvant treatments were compared to patients who underwent therapy exclusively adjuvantly. We investigated the K-RAS mutational profile, the c-MET over-expression along with patients' survivals curves...
April 21, 2017: Pathology, Research and Practice
https://www.readbyqxmd.com/read/28552047/t-dm1-in-the-neo-adjuvant-treatment-of-her2-positive-breast-cancer-impact-of-the-kristine-trio-021-trial
#8
Alicia Fc Okines
BACKGROUND: Neo-adjuvant chemotherapy (NAC) can facilitate breast conservation, allows in vivo testing of chemotherapy sensitivity and provides a route to accelerated approval of new therapies. For HER2 positive breast cancer, the anti-HER2 monoclonal antibody, trastuzumab, is a standard component of neo-adjuvant therapy for HER2 positive breast cancer. Pertuzumab is an anti-HER2 monoclonal antibody with a distinct binding site to trastuzumab, which prevents HER2 receptor dimerisation...
May 28, 2017: Reviews on Recent Clinical Trials
https://www.readbyqxmd.com/read/28549309/switching-between-intravenous-and-subcutaneous-trastuzumab-safety-results-from-the-prefher-trial
#9
Joseph Gligorov, Giuseppe Curigliano, Volkmar Müller, Ann Knoop, Valerie Jenkins, Sunil Verma, Stuart Osborne, Sabine Lauer, Zuzana Machackova, Lesley Fallowfield, Xavier Pivot
AIM: To assess the safety and tolerability of switching between subcutaneous (SC) and intravenous (IV) trastuzumab in the PrefHer study (NCT01401166). PATIENTS AND METHODS: Patients with HER2-positive early breast cancer completed (neo)adjuvant chemotherapy and were randomised to receive four cycles of SC trastuzumab, via single-use injection device (SID; Cohort 1) or hand-held syringe (Cohort 2), followed by four cycles of IV, or vice versa (the crossover period presented here) as part of their 18 standard cycles of adjuvant trastuzumab treatment...
May 23, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28538407/unusual-jaw-metastasis-from-squamous-cell-lung-cancer-in-heavy-smoker-two-case-reports-and-review-of-the-literature
#10
Aldo Pezzuto, Michelangelo Morrone, Elidon Mici
RATIONALE: Jaw metastasis is a very rare condition associated with lung cancer evolution. In this paper we present two cases of patients who underwent different approach.Lung cancer is the leading cause of cancer related death worldwide. Survival depends on the staging and biology of tumor. Smoking may affect the prognosis. PATIENT CONCERNS: There are herein reported the cases of two patients affected by squamous cell lung cancer with spread to mandibular bone. DIAGNOSES: In the first case a computed tomography (CT scan) showed a large mass located in upper right lung , then bronchoscopy was performed with biopsies and the histology revealed a squamous cell carcinoma P63+ and TTF-...
May 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28529719/contemporary-surgical-management-of-synchronous-colorectal-liver-metastases
#11
REVIEW
Danielle Collins, Heidi Chua
Historically, the 5-year survival rates for patients with stage 4 (metastatic) colorectal cancer were extremely poor (5%); however, with advances in systemic chemotherapy combined with an ability to push the boundaries of surgical resection, survival rates in the range of 25-40% can be achieved. This multimodal approach of combining neo-adjuvant strategies with surgical resection has raised a number of questions regarding the optimal management and timing of surgery. For the purpose of this review, we will focus on the treatment of stage 4 colorectal cancer with synchronous liver metastases...
2017: F1000Research
https://www.readbyqxmd.com/read/28526012/the-pregnancy-and-fertility-prefer-study-an-italian-multicenter-prospective-cohort-study-on-fertility-preservation-and-pregnancy-issues-in-young-breast-cancer-patients
#12
Matteo Lambertini, Paola Anserini, Valeria Fontana, Francesca Poggio, Giuseppina Iacono, Annalisa Abate, Alessia Levaggi, Loredana Miglietta, Claudia Bighin, Sara Giraudi, Alessia D'Alonzo, Eva Blondeaux, Davide Buffi, Francesco Campone, Domenico F Merlo, Lucia Del Mastro
BACKGROUND: Fertility and pregnancy issues are of key importance for young breast cancer patients. Despite several advances in the field, there are still multiple unmet needs and barriers in discussing and dealing with these concerns. To address the significant challenges related to fertility and pregnancy issues, the PREgnancy and FERtility (PREFER) study was developed as a national comprehensive program aiming to optimize care and improve knowledge around these topics. METHODS: The PREFER study is a prospective cohort study conducted across several Italian institution affiliated with the Gruppo Italiano Mammella (GIM) group evaluating patterns of care and clinical outcomes of young breast cancer patients dealing with fertility and pregnancy issues...
May 19, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28521471/preoperative-peripheral-blood-neutrophil-count-predicts-long-term-outcomes-following-hepatic-resection-for-colorectal-liver-metastases
#13
Koichiro Haruki, Hiroaki Shiba, Yuki Fujiwara, Kenei Furukawa, Tomonori Iida, Masahisa Ohkuma, Masaichi Ogawa, Yuichi Ishida, Takeyuki Misawa, Katsuhiko Yanaga
Preoperative systemic inflammatory response is associated with a poor long-term prognosis following resection surgery for malignant tumors. Several markers of systemic inflammation have been reported to be associated with the outcome; however, they have not currently been fully investigated. Therefore, the association between preoperative peripheral blood neutrophil count and oncological outcome following hepatic resection for colorectal liver metastasis (CRLM) was retrospectively investigated. The present study comprised 89 patients who had undergone hepatic resection for CRLM between January 2000 and March 2010...
May 2017: Oncology Letters
https://www.readbyqxmd.com/read/28509807/treatment-of-retroperitoneal-sarcoma-current-standards-and-new-developments
#14
Winan J van Houdt, Shane Zaidi, Christina Messiou, Khin Thway, Dirk C Strauss, Robin L Jones
PURPOSE OF REVIEW: Retroperitoneal sarcomas are rare tumors and with complex treatment. In this manuscript we give an overview of current standards in treatment of this disease and discuss new developments. RECENT FINDINGS: Surgery with complete resection of the primary tumor is still the only curative modality. The role of preoperative radiotherapy is not clear and is currently being investigated in a clinical trial. Neo-adjuvant chemotherapy is not the standard of care but can be considered occasionally when complete resection is uncertain...
July 2017: Current Opinion in Oncology
https://www.readbyqxmd.com/read/28491135/highlights-from-the-15th-st-gallen-international-breast-cancer-conference-15-18-march-2017-vienna-tailored-treatments-for-patients-with-early-breast-cancer
#15
Consuelo Morigi
The 15th St Gallen International Breast Cancer Conference was held in Vienna for the second time, from 15th-18th March 2017. 4000 people from 105 countries all over the world were invited to take part in the event. The real highlight of the conference was the last day with the International Consensus Session which was chaired by around 50 experts on breast cancer worldwide. With reference to data from scientific research, the consensus panel tried to offer guidelines for the management of breast cancer with the aim of providing patients with optimal treatment...
2017: Ecancermedicalscience
https://www.readbyqxmd.com/read/28488799/systematic-review-of-exercise-training-in-colorectal-cancer-patients-during-treatment
#16
REVIEW
S J van Rooijen, M A Engelen, C Scheede-Bergdahl, F Carli, R M H Roumen, G D Slooter, G Schep
Colorectal cancer surgery results in considerable postoperative morbidity, mortality and reduced quality of life. As many patients will undergo additional (neo)adjuvant therapy, it is imperative that each individual optimize their physical function. To elucidate the potential of exercise in patient optimization, we investigated the evidence for an exercise program before and after surgical treatment in colorectal cancer patients. A systematic review was conducted according to the Cochrane Handbook for Systematic Reviews of Interventions, the guidelines of the Physical Therapy Journal and the PRISMA guidelines...
May 10, 2017: Scandinavian Journal of Medicine & Science in Sports
https://www.readbyqxmd.com/read/28482877/electronic-patient-self-reporting-of-adverse-events-patient-information-and-advice-erapid-a-randomised-controlled-trial-in-systemic-cancer-treatment
#17
Kate Absolom, Patricia Holch, Lorraine Warrington, Faye Samy, Claire Hulme, Jenny Hewison, Carolyn Morris, Leon Bamforth, Mark Conner, Julia Brown, Galina Velikova
BACKGROUND: eRAPID (electronic patient self-Reporting of Adverse-events: Patient Information and aDvice) is an internet based system for patients to self-report symptoms and side effects (adverse events or AE) of cancer treatments. eRAPID allows AE reporting from home and patient reported data is accessible via Electronic Patient Records (EPR) for use in routine care. The system can generate alerts to clinical teams for severe AE and provides patient advice on managing mild AEs. The overall aims of eRAPID are to improve the safe delivery of cancer treatments, enhance patient care and standardise AE documentation...
May 8, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28469332/taxane-combination-chemotherapy-in-breast-cancer-experience-from-a-tertiary-cancer-centre-in-india
#18
Jyoti Bajpai, Deepa Susan, Vijay Patil, Reena Nair, Jaya Ghosh, R A Badwe, Sudeep Gupta
AIMS: Docetaxel, Doxorubicin, Cyclophosphamide (TAC) is an intensive chemotherapy regimen; however, being highly myelosuppressive, its usage is limited in developing countries and hence merits exploration for feasibility and efficacy. MATERIALS AND METHODS: This was a retrospective audit of medical records of breast cancer patients receiving TAC chemotherapy) from 2004 to 2008. Demographic details, toxicity, and outcome analysis were carried out. RESULTS: A total of 133 patients (126 in [neo] adjuvant and 7 in metastatic setting) received TAC chemotherapy...
January 2017: Indian Journal of Medical and Paediatric Oncology
https://www.readbyqxmd.com/read/28464906/adjuvant-radiotherapy-after-radical-cystectomy-for-patients-with-muscle-invasive-bladder-cancer-a-phase-ii-trial
#19
Valérie Fonteyne, Piet Dirix, Sara Junius, Elke Rammant, Piet Ost, Gert De Meerleer, Martijn Swimberghe, Karel Decaestecker
BACKGROUND: Neo-adjuvant chemotherapy followed by radical cystectomy with extended pelvic lymph node dissection is considered to be the treatment of choice for patients with muscle invasive bladder cancer (MIBC). Despite this aggressive treatment the outcome is poor and ultimately, 30% of the patients with ≥pT3 tumors develop a pelvic recurrence. We hypothesize that postoperative adjuvant external beam radiotherapy (EBRT) might prevent local and lymph node recurrence and improve disease free- and overall survival as loco-regional recurrence is linked to the development of distant metastasis...
May 2, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28460622/intravesical-chemotherapy-and-chemohypherthermia-in-non-muscle-invasive-bladder-cancer-an-overview-on-drug-administration-technologies-and-pharmacokinetics
#20
Fabio Campodonico, Savino Di Stasi, Gad M Lev, Carlo Terrone, Luca Bongiovanni, Francesca Mattioli, Vincenzo Pagliarulo, Carlo Introini
BACKGROUND: Tumor recurrence is the most expected clinical event after the resection of non-muscle invasive bladder cancer, depending on histological findings of the initial lesion. In patients with low and intermediate risk of disease, the intravesical instillation of chemotherapy agents is recommended as a standard treatment to reduce recurrences. METHODS: A comprehensive review covering various aspects of different treatments with intravesical drugs is presented...
April 26, 2017: Current Drug Metabolism
keyword
keyword
109145
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"